ODI Pharma AB (publ) reported earnings results for the second quarter and six months ended December 31, 2022. For the second quarter, the company reported sales was SEK 0.073276 million compared to SEK 0.45862 million a year ago. Revenue was SEK 0.080524 million compared to SEK 0.516768 million a year ago. Net loss was SEK 1.74 million compared to SEK 1.4 million a year ago. Basic loss per share from continuing operations was SEK 0.11 compared to SEK 0.09 a year ago.
For the six months, sales was SEK 0.101282 million compared to SEK 0.45862 million a year ago. Revenue was SEK 0.126386 million compared to SEK 0.517085 million a year ago. Net loss was SEK 3.42 million compared to SEK 2.58 million a year ago. Basic loss per share from continuing operations was SEK 0.22 compared to SEK 0.17 a year ago.